Search results with tag "In oncology"
Efficacy endpoints in Oncology
www.lexjansen.comEfficacy endpoints in Oncology Angelo Tinazzi, Cytel Inc., Geneva, Switzerland ABSTRACT The evaluation of efficacy in oncology studies, in particular for solid tumors, is pretty standard and well defined by several regulatory guidance (e.g. EMA and FDA), including some specific cancer type guidance (e.g. NSCLC from FDA).
NCCN Clinical Practice Guidelines in Oncology (NCCN ...
www2.tri-kobe.orgNCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines ... Efficacy was noted in Stage IIIB, IIIC, and Stage IV-M1a disease and was more likely in patients who were treatment naive." ME-8 • Treatment of Local, Satellite, and/or In-transit Recurrence:
NCCN Clinical Practice Guidelines in Oncology (NCCN ...
www2.tri-kobe.orgThere are limited data on the efficacy of bevacizumab in the recurrence therapy setting for patients previously treated with bevacizumab. • Footnote "m" added: "If response after chemotherapy, bevacizumab can be continued as maintenance therapy until disease progression or unacceptable toxicity." OV-6
Clinical Development Success Rates and Contributing ...
pharmaintelligence.informa.com• Immuno-oncology therapies provide a rare pocket of success in oncology R&D with an overall LOA of 12.4% vs 5.3% for all oncology approaches. • Rare disease therapies were notably successful with an overall LOA of 17.0%. • Chronic, high prevalence disease therapies were less successful with an overall LOA of 5.9%.
Regulatory Challenges of Global Drug Development in …
prs-clinical.comTopics • General global R&D issues • Regulatory issues with global oncology drug development • US FDA initiatives in oncology • International comparisons
NCCN Task Force Report: Evaluating the Clinical …
www.nccn.orgJNCCN NCCN Task Force Report: Evaluating the Clinical Utility of Tumor Markers in Oncology